Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant
Adherence is one of the biggest challenges physicians face in diabetes management.
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel
Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest
The science behind new diabetes drugs underscores how far we've come from the days of purified pork insulin. Even so, most ads stick to traditional copy.
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
Sproutel CEO Aaron Horowitz talks about how Jerry the Bear came to life and why endocrinologists are stocking the bear in their offices.